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Abstract: Prescribing pattern surveys are one of the pharmacoepidemiological techniques that 
provide an unbiased picture of prescribing habits. Prescription surveys permit the identifica-
tion of suboptimal prescribing patterns for further evaluation. The aims of this study were to 
determine the prescribing trend, adherence of the prescribers to the guideline, and the impact of 
drug expenditure on drug utilization at the cardiac clinic of Penang Hospital, Malaysia. This was 
a cross-sectional study. Demographic data of the patients, diagnoses and the drugs prescribed 
were recorded. The average drug acquisition costs (ADAC) were calculated for each antihy-
pertensive drug class on a daily and annual basis. Adherence to the guideline was calculated as 
a percentage of the total number of patients. A total of 313 individuals fulfilled the inclusion 
criteria. The average age of the study population was 59.30 ± 10.35 years. The mean number 
of drugs per prescription in the study was 2.09 ± 0.78. There were no significant differences in 
the demographic data. Antihypertensive drugs were used in monotherapy and polytherapy in 
20.8% and 79.2% of the patients, respectively. Adherence to the guideline regarding prescrip-
tion occurred in 85.30% of the patients. The lowest priced drug class was diuretics and the 
highest was angiotensin-receptor blockers. In conclusion, the total adherence to the guideline 
was good; the adherence percentage only slightly decreased with a co-existing comorbidity 
(such as diabetes mellitus). The use of thiazide diuretics was encouraged because they are well 
tolerated and inexpensive, and perindopril was still prescribed for diabetic patients since it is 
relatively cheap (generic drug) and its daily dosage is beneficial.
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Introduction
Cardiovascular disease (CVD) is responsible for one-third of deaths worldwide.1 
  Hypertension is an extremely prevalent risk factor for CVD. It is a common health 
problem worldwide due to increasing longevity and the prevalence of contributing 
factors.2,3 The Ministry of Health of Malaysia showed that cardiovascular disease is 
the main cause of death in government hospitals.4 Data from the Third National Health 
and Morbidity Survey of 2006 (NHM 3)5 showed that all of the risk factors which 
lead to the most common chronic diseases in Malaysia had increased in prevalence 
compared to the last survey in 1996. The prevalence of hypertension (HT) is now 43% 
(up from 33%) in people aged 30 years and older, diabetes mellitus (DM) 14.9% (up 
from 8.3%) and overweight/obesity has increased in prevalence to 43% (up from 27%).6 
While an increase in treatment rate has been observed, the control rate is still inadequate. 
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According to NHM 3 and the Institute of Health Management 
of the Ministry of Health on the outpatient management of 
hypertension in government clinics data, only 26%–28.5% of 
patients with hypertension who were receiving drug treatment 
achieved their target blood pressure (BP).
Prescribing pattern surveys are one of the pharmacoepi-
demiological techniques that provide an unbiased picture 
of prescribing habits. Prescription surveys permit the iden-
tification of suboptimal prescribing patterns for further 
  evaluation. Published guidelines help in clinical decision 
making, decrease practice variations, guide correctness, 
and measure the quality of health care.7,8 Many studies have 
connected poor blood pressure control with poor adherence 
to hypertension guidelines.9–15 In addition to the importance 
of guideline adherence, the drug expenditure plays a role in 
treatment decisions since many new, expensive drugs are 
being prescribed at an increasing rate.16 A study performed 
by Salman et al in 1999 indicated that knowledge of drug 
costs has an effect on physician prescription patterns, which 
is a fact that could lead to appreciable savings in drug costs 
by prescribers.17 Non-compliance to the guidelines may 
increase risk factors and other complications. Several studies 
used either prescription or drug dispensing data to evaluate 
guideline adherence worldwide, but few data are available 
in Malaysia, which has heterogeneous ethnic groups. This 
study evaluated physicians’ prescribing patterns of anti-
  hypertensive drugs, their compliance towards the recom-
mended guideline and compared the costs of antihypertensive 
drugs based on the recommended guideline.
Methods and study design
This was a cross-sectional study conducted in the cardiology out-
patient clinic of Penang General Hospital for 4 months in 2008, 
after approval was obtained from the Ministry of Health Ethical 
Committee MREC (Medical Research Ethics Committee) and 
from the Penang General Hospital ([PGH] Penang, Malaysia). 
Demographic data, diagnoses and drug prescriptions were 
gathered from medical records of patients who attended the 
outpatient clinic during the study and received antihypertensive 
therapy for 5 years. The hypertensive patients were divided into 
two groups (primary hypertension and hypertension with asso-
ciated clinical conditions) according to a risk assessment using 
World Health Organization/International Society of Hyperten-
sion (WHO/ISH) guidelines for the management of hyper-
tension.18 The inclusion criteria of this study were all primary 
hypertensive patients and hypertensive patients with a comor-
bidity (diabetes mellitus and ischemic heart disease) who visited 
the outpatient clinic and were .18 years old. The exclusion 
criteria were all hypertensive patients with renal disease,   thyroid 
disease, heart failure, liver disease, coronary obstructive airway 
disease, myocardial infarction or patients who have undergone 
operative revascularization of the coronary vessels and patients 
with no clear diagnosis or laboratory data.
The antihypertensive drugs were classified into six 
therapeutic drug classes: β-blockers (BB), calcium-channel 
blockers (CCB), diuretics (D), angiotensin-converting enzyme 
inhibitors (ACEI), angiotensin-receptor blockers (ARB) and 
other antihypertensive agents (α1-blockers,   central α2-agonists, 
and direct vasodilators). Monotherapy was defined as the use 
of one antihypertensive drug with only one active ingredient. 
Patients who were taking more than one active ingredient, 
either in one combination (except for a combination of two 
diuretics, such as Moduretic®, First DataBank Inc, South San 
Francisco, CA) or as two different, single pills were defined 
as receiving polytherapy.19 The drug costs were obtained from 
the pharmacy department (Penang General Hospital).
The average drug acquisition costs (ADAC, the costs of 
buying the drugs) were calculated for each drug class on a 
daily and annual basis and the percentage expenditure cost 
(%EC) was also calculated, using the following equations.20
ADAC (daily) =   Total daily cost of drug class/Number of 
prescriptions of the drug class   (multiplied 
by 365 for the annual basis).
%EC =   (Expenditure cost (EC) of the class/Total expenditure 
of all prescriptions) × 100
Adherence to the guideline (Management of Hypertension, 
Academy of Medicine of Malaysia, Jalan Tun Razak, Kuala 
Lumpur) was calculated as a percentage of the total number of 
patients.21,22 The percentages were calculated as follows:
1.  The first step was to specify the treatment guideline for 
each group of patients:
a.  Essential HT (use of D or BB as a first-line therapy 
or added onto another drug therapy).
b.  HT + DM (use of an ACEI or ARB as a first-line therapy 
or added onto another antihypertensive drug therapy).
c.  HT + IHD (use of a BB or CCB as a first-line therapy or 
added onto another antihypertensive drug therapy).
d.  HT + IHD + DM (use of an ACEI or ARB and BB 
or CCB as a first-line therapy or added onto another 
antihypertensive drug therapy).
2.  The second step was to calculate the percentage of 
  adherence (%A) to the guideline:
  %A =   (Total number of cases that followed the  
guideline/total number of patients) × 100
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The expenditure per prescription for each diagnosis group 
(adherence and non-adherence to treatment guideline) was 
the total of the average expenditure for each drug class used 
in the treatment of related diagnoses.
Statistical analysis
The data were processed and presented using the SPSS 
15.0 statistical program software (IBM Corporation, 
Armonk, NY). Independent t-tests, Chi-square, ANOVA and 
  Mann-Whitney U tests were used when appropriate to compare 
the differences between drug group utilization, age groups, 
gender, race, ADAC and adherence to the guidelines.
Results and discussion
Demographic characteristics  
and prescribing pattern
Out of 500 patients with hypertension, only 313 individuals 
fulfilled the inclusion criteria. The data was expressed as 
mean ± standard deviation (SD). The demographic data are 
shown in Table 1.
In our results, 51 patients (16.29%) had essential hyper-
tension, 32 (10.22%) had hypertension with diabetes mellitus 
type 2 (DM), 122 (38.97%) had hypertension with ischemic 
heart disease (IHD), and 108 (34.50%) had hypertension with 
IHD and DM. The average age of the study population was 
59.30 ± 10.35 years old. There was a significant difference 
between the average ages of males (58.21 ± 10.20) and females 
(61.86 ± 10.32) (P , 0.01, t(2.877) = 311; P = 0.004), which 
is similar to the findings of a previous study in Malaysia.22 The 
mean age of Malay patients was the lowest compared to the 
mean age of the other races. There was a significant difference 
between the mean ages of the different races (F (3,309) = 6.12; 
P , 0.001). Most of the patients (69.96%) were below 65 years 
of age. The percentages of Malay and Chinese hypertensive 
patients were approximately equal (36.4% Malay, 35.8% 
  Chinese). This result is inconsistent with the findings of a pre-
vious study which showed that Chinese patients had the great-
est prevalence of hypertension (30.6%), followed by Malays 
(26.7%) and Indians (25.1%).23 The reason for this could be 
due to the fact that the sample size in our study was smaller 
compared to the study by Rampal et al or because the prevalence 
of hypertension in Penang State needs to be reassessed, which 
was not covered by Rampal et al or our study.23
A total of 655 antihypertensive drugs were prescribed by 
the physicians. The mean number of drugs per prescription 
in this study was 2.09 ± 0.78, which is fewer than the values 
reported in studies in developing countries (2.2–3.8 drugs per 
prescription) such as Jordan, Yemen, Nigeria and Iran.19,24–27 
However, this value is somewhat similar to values found in 
developed countries (1.3–2.2 drugs per prescription),28 which 
gives an indication that the Malaysian health prescribing 
pattern is comparable to patterns in developed countries. No 
significant difference was found between the mean number of 
antihypertensive drugs prescribed in males (2.04 ± 0.77) and 
females (2.20 ± 0.83), (P . 0.05, t(1.604) = 311; P = 0.123). 
This result is inconsistent with the results reported by other 
investigators.29,30 Other researchers reported that, compared 
with men, women used more medicines and requested treat-
ment more frequently.25,27,31–33 No significant difference was 
found between the age groups (younger than 65 and older 
than 65; 2.05 ± 0.72, and 2.18 ± 0.92, respectively, (P . 0.05, 
t(1.29) = 311; P = 0.243) regarding the mean number of 
antihypertensive drugs per prescription. The same result was 
reported by Sepehri et al in 2008 in Iran.19 The frequency 
of use of the six antihypertensive drug classes in relation to 
gender, age, and race is shown in Table 2.
Table 1 The demographic characteristics of 313 hypertensive 
patients
Male (%) Female (%) All patients (%)
gender (%) 219 (70) 94 (30) 313 (100)
Age group (years)†
 , 65 163 (74.4) 56 (59.6) 219 (69.96)
 $ 65 56 (25.6) 38 (40.4) 94 (30.03)
Mean age in  
years (±SD)‡
58.21 (±10.20) 61.86 (±10.32) 59.3 (±10.35)
Median (years) 57.00 62.00 58.0
Race
  Malay 84 (26.8) 30 (9.6) 114 (36.4)
  Chinese 70 (22.4) 42 (13.4) 112 (35.8)
  Indian 61 (19.5) 21 (6.7) 82 (26.2)
  Others 4 (1.3) 1 (0.3) 5 (1.6)
Notes: †X² = 6.907, df = 1; P = 0.009; ‡t(2.877) = 311; P = 0.004.
Table 2 The prescription frequency of the six antihypertensive 
drug classes by cardiologists in hypertensive patients according to 
gender, age and race
Drug classes Sex (%) Age (%) Race (%)
Female Male ,65 $65 M C I
BB 84.0 86.8 85.4 87.2 87.7 89.3 78.0
CCB 20.2 19.2 16.9 25.5 14.9 17.9 26.8
ACEI†,‡ 67.0 70.3 75.3 24.7 78.1 62.5 67.1
D* 18.7 36.2 21 30.9 28.1 20.5 20.7
ARB† 10.6 7.3 5 16 3.5 12.5 7.8
Others  
(prazocin)
5.3 3.2 2.7 6.4 0.9 7.1 3.7
Notes:  †Significant result in respect to age;  ‡significant result in respect to race; 
*significant result in respect to sex; significance level (P , 0.05).
Abbreviations: M, Malaysian; C, Chinese; I, Indian; ACEI, angiotensine-converting 
enzyme  inhibitors;  ARB,  angiotensine-receptor  blockers;  BB,  β-blocker;  CCB, 
calcium-channel blockers; D, diuretic. 
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Only diuretics were used significantly more in males than 
females. This result is supported by the previous finding that 
male patients who had a higher relative incidence of coronary 
arterial disease received more diuretics than females in the 
treatment of hypertension.34 Regarding the age groups, there 
were no significant differences in terms of the frequency 
of prescribing CCB and BB between the younger and older 
patients. This pattern is inconsistent with the results of a 
previous study where geriatric patients were less frequently 
prescribed BB. This was because adverse drug effects such 
as fatigue and postural hypotension are more common in 
older patients treated with BB agents, and older subjects also 
seem to respond less well to such agents.35 Moreover, elderly 
patients appear to have a good blood pressure response to 
calcium-channel blockers, most likely due to their low renin 
levels and salt status.36–38 Consequently, it is important to 
follow the recommendation of prescribing BB to younger 
patients and CCB to elderly patients. Regarding the use of 
ACEI, the results showed a highly significant difference 
between the age groups, with the highest frequency of use 
of this drug class in younger patients. This is because many 
patients who are at higher risk of cardiovascular events, as 
well as ACEI, have been shown to reduce morbidity and 
mortality.39 Diuretics are recommended for use in older 
patients;40 however, in our study the elderly patients had a 
higher frequency for using it.
Only ACEI and ARBs showed significant differences in the 
prescription percentages between the different racial groups, 
which may have been due to the side effects of ACEI. It was 
previously reported that relatively more incidences of ACEI 
causing cough were found in Chinese (44%) patients compared 
to Caucasian patients, which may explain the high percentage of 
ARB usage in Chinese patients.41 No significant difference was 
found in the mean number of antihypertensive drugs prescribed 
between the different racial groups (P . 0.05, F (3,309) = 2.46; 
P = 0.063). Antihypertensive drugs were used as monotherapy 
and polytherapy in 20.8% and 79.2% of the patients, respec-
tively. The percentage of monotherapy was lower than found 
in a previous study in Malaysia 2005.6 The dosage strength 
and frequency of drugs in both monotherapy and polytherapy 
in our study and the previous study were within the lowest 
range of the usually recommended therapeutic doses. Rashid 
estimated that 81% of patients with hypertension in Malaysia 
were prescribed only one anti-hypertensive medication and that 
many of these patients were given suboptimal doses,6 which 
could explain the incidence of uncontrolled hypertension in 
many patients in Malaysia. Patients on combination therapy 
(particularly combinations comprising diuretics) are probably 
more likely to attain the target blood pressure than patients who 
are on monotherapy or combination therapy without diuretics.
Physicians in Malaysia were found to prescribe drugs 
at a lower dosage than is prescribed in Western countries. 
This was thought to be due to the fact that Malaysian people 
generally have a smaller body size than Caucasians, as based 
on published literature. In addition, evidence has shown 
that Asian populations also absorb certain drugs better than 
Caucasians. Nevertheless, there is no evidence to prove that 
the response to pharmacotherapy in Asians differs from 
that of Caucasians.6 The antihypertensive medications most 
frequently used in the cardiology outpatient clinic of Penang 
Hospital, Malaysia, are shown in Table 3.
Prescribing pattern and prescriber 
adherence of antihypertensive drugs  
in patients with essential hypertension
There were only 51 (16.29%) patients who had essential 
hypertension. The prescribing pattern of these patients 
was as follows: only 18 (35.3%) were on monotherapy 
Table 3 The antihypertensive medications most frequently used 
in  the  cardiology  outpatient  clinic  of  Penang  general  Hospital, 
Malaysia
Drug group Name of drug Frequency Percentage
BB 269 85.9
Atenolol 39 12.5
Metoprolol 209 66.8
Carvedilol 8 2.6
Bisoprolol 11 3.5
Propranolol 2 0.6
ACEI 218 69.6
Enalapril 32 10.2
Captopril 13 4.2
Perindopril 173 55.3
Diuretic 75 24
Hydrochlorothiazide 32 10.2
Furosemide 40 12.8
Hydrochlorothiazide/ 
amiloride
3 1
ARB 25 7.9
Losartan 7 2.2
Telmisartan 14 4.5
Valsartan 3 1
Irbisartan 1 0.3
CCB 59 18.8
Amlodipine 23 7.3
Nifedipine 3 1
Diltiazem 33 10.5
Others 12 3.8
Prazocin 12 3.8
Abbreviations: BB, β-blocker; ACEI, angiotensin-converting enzyme inhibitors; 
ARB, angiotensin-receptor blockers; CCB, calcium-channel blockers.
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and 33 (64.7%) were on polytherapy. The most frequently 
prescribed drug regimen was two-drug therapy (47.1%). 
BBs were the most   common ditherapy drugs used in 
combination in these patients (N = 41, 80.4%), followed 
by ACEI, (N = 27, 52.9%) and diuretics (N = 14, 27.5%), 
while ARBs and CCB consist only (N = 7, 13.7%) for 
each and the least commonly used drug class was alpha-
blockers (N = 1, 2%). The drug class most frequently used 
in monotherapy was also BB (N = 12, 66.7%), and the drug 
class used the least was diuretics (N = 1, 5.6%). For the 
two-drug regimen, the most common prescription combi-
nation was a BB and ACEI (N = 13, 54.2%), and the least 
common one was a BB and CCB (N = 1, 4.2%). BB were 
found in about 83.3% of all two-drug combinations, while 
diuretics were only found in about 20.83%. The frequency 
of diuretics prescribed in this study was very low, despite 
them being recommended in treatment guidelines, which 
is supported by many randomized, long-term, controlled 
clinical trials that showed a reduction in both cerebrovascu-
lar and cardiovascular morbidity.   Diuretics should be used 
as first-line therapy for most patients with hypertension, 
either alone or in combination with one of the other classes 
(ACEI, ARB, BB, CCB).34,39,42
In spite of national recommendations, the use of diuretics 
has gradually reduced over the past 15 years. The reasons 
for this include the rapid advancement of other medications 
and the perception that diuretics produce adverse metabolic 
effects and do not decrease CVD events. However, available 
data suggest that: (1) alterations in glucose and cholesterol 
metabolic processes are minor, particularly with the smaller 
doses now being used; (2) diuretics reduce the rates of 
morbidity and mortality from cardiovascular diseases in 
hypertensive patients, even in those with hyperlipidemia or 
diabetes; and (3) fears about hypokalemia-induced arrhyth-
mias have been exaggerated.43 Although there was a high 
percentage of adherence to the guideline (86.27%) (Table 4) 
due to the high percentage of BB use in patients, strong, 
high quality, evidence exists favouring the use of low-dose 
thiazide diuretics in the treatment of hypertension in order 
to reduce blood pressure and rates of cardiovascular disease 
and death.42
Prescription pattern and prescriber 
adherence in patients with hypertension 
and diabetes mellitus
There were 32 (10.22%) patients who had coexisting 
hypertension and type 2 DM. Eight patients (25%) were 
on a single agent, which is lower than recommended since, 
regardless of the target BP level; a tight control of BP 
is important for reducing CVD mortality and morbidity 
rates.44 In order to reach the target BP in diabetics, two or 
more drugs are generally required.45 Monotherapy with 
ACE inhibitors was prescribed in 72% of patients with 
type 2 DM, which is inadequate depending on the evidence 
trial.44,46 ACE inhibitors are recommended because they are 
known to enhance insulin sensitivity and slow down the 
progression of diabetes,44,47 and ACEI also have the abil-
ity to slow down the progression of nephropathy in type 
2 diabetes compared to other antihypertensive drugs.48,49 
Similar to ACEI, ARBs have advantageous effects in 
slowing down the progression of diabetes, and they also 
possess the other cardiovascular and renal benefits found 
with ACEI.50 The percentage of adherence to the guideline 
was 78.13% (Table 4), which showed that the prescribing 
trends of patients with DM need to be reassessed.
Prescription pattern and prescriber 
adherence in patients with hypertension 
and ischemic heart disease
There were 122 patients (38.97%) who had hypertension 
with IHD. The most frequent drug regimen used was the 
combination of an ACEI and BB (82.66%). The prescrib-
ing frequency of BB was high (89.3%). According to the 
guideline, BB are the first drugs of choice for the treat-
ment of hypertension in patients with CAD.34,39,51,52 On the 
other hand, CCB should be substituted for BB when BP 
remains elevated or angina persists or there are adverse 
side effects or if contraindicated.53 According to all of the 
above evidence and in relation to the prescribing pattern 
in this group of patients, it was found that the clinicians 
followed the recommendations of the Malaysian guide-
lines, with a high percentage of adherence of 95.08%   
(Table 4).
Table 4   Total  adherence  to  the  prescription  guidelines  by 
physician in the outpatient clinic
Category (no of  
prescriptions)
No of cases  
not following  
guideline
No of cases  
following  
guideline
Adherence   
(%A)
Essential HT (51) 7 44 86.27
HT + DM (32) 7 25 78.13
HT + IHD (122) 6 116 95.08
HT + DM + IHD (108) 26 82 75.92
Total adherence (%A) / / 85.30
Abbreviations:  DM,  Diabetes  mellitus;  IHD,  ischemic  heart  disease;  HT, 
hypertension.
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Prescription pattern and prescriber 
adherence in patients with hypertension, 
ischemic heart disease and diabetes mellitus
There were 108 cases (34.5%) with hypertension, IHD and 
DM; of these, 96 patients (88%) were on polytherapy and 
the remaining patients were on monotherapy (11.1%). The 
most frequently prescribed drug class by physicians for this 
group of patients was BB (88%), followed by ACEI (73.1%) 
and their combination (37%). As previously discussed for 
patients with DM, this patient population normally requires 
two or more hypertensive agents for BP treatment, involving 
ACEI as a first-line treatment with BB for the treatment of 
IHD. In this study, 58.33% of the patients received BB as 
monotherapy. Therefore, the level of success in achieving 
the target BP, besides good glycemic control, is questionable 
in Malaysian populations.6 The percentage of adherence to 
the guideline was 75.92% (Table 4), which indicates that 
the prescribing pattern of this sub-population should be 
reassessed.
Table 5 Drug acquisition (daily and annual) costs of the different 
antihypertensive drugs prescribed in the outpatient clinic
Drug classes Average drug  
acquisition cost per  
prescription (RM)
% of class 
expenditure   
cost
Per day Per year
BB 0.205 74.82 30.03
ACEI 0.225 82.12 26.47
ARB 1.191 434.71 16.22
CCB 0.718 262.07 23.46
Diuretics 0.05 18.25 2.02
Others (prazocin) 0.27 98.55 1.78
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-
receptor blockers; BB, β-blocker; CCB, calcium-channel blockers; RM, Malaysian 
Ringgit (equal approximately to 0.30 USD).
100
Others D CCB ARB ACEI BB
Antihypertensive drug class
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20
40
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Figure 1 Utilization and expenditure patterns of antihypertensive drugs in out patient cardiac clinic.
Abbreviations: BB, β-blocker; ACEI, angiotensine-converting enzyme inhibitors; ARB, angiotensine-receptor blockers; CCB, calcium-channel blockers; D, diuretics.
Antihypertensive drug expenditure
The daily and annual drug acquisition costs per prescription (one 
Malaysian Ringgit (RM) equal approximately to 0.30 USD) of 
the various antihypertensive drugs are presented in Table 5.
The ranking in terms of cost from the highest to the 
lowest was: ARB . CCB . AB . ACEI . BB . D. 
Drug   utilization and costs are represented in Figure 1. The 
antihypertensive cost analysis showed that ARBs accounted 
for 16.22% of the total antihypertensive drug costs incurred, 
although their utilization only represented 7.9% of the over-
all antihypertensive drugs. Also, the cost of CCB was high 
(23.46%) in relation to its utilization percentage (18.8%) 
(Figure 1). The explanation of highest cost is that the use of 
innovator drugs and highest frequency dose for CCB drugs 
add more cost on drug expenditure per prescription that is 
available in Penang General Hospital. The cheapest drugs 
were the diuretics, which can offer some advantages over 
other drugs used for controlling blood pressure in terms of 
decreasing cardiovascular morbidity and mortality events.34,39 
It was not surprising that the expenditure on ACEI out of 
the total antihypertensive drug expenditure was relatively 
low because the most commonly used drug of this class was 
perindopril. The median dosage frequency was about once 
daily, at the lowest dose strength (2 mg), and it is a generic 
drug with a low cost. The frequency of metoprolol usage was 
also high (66.8% out of all BB drugs used) and the median 
dosage frequency was 50 mg bd. This added additional costs 
to BB expenditure compared to the cheapest BB, atenolol. 
However, the use of thiazides as a first-choice therapy would 
result in substantial cost savings due to their favourable 
price.54 Thus, the medical profession should release a clear 
statement: thiazides are the most common agents for the 
treatment of hypertension due to their effectiveness and lower 
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cost.55–58 The treatment costs of essential hypertension with 
and without comorbidity are shown in Table 6.
There were extremely significant differences between the 
drug costs in each group by both following and not following 
the guideline for the treatment of hypertension with comor-
bidity. The results showed a decrease in the treatment costs 
of hypertension with a coexisting disease in cases where the 
guidelines were not followed, indicating   inadequate   treatment. 
In contrast, for the treatment of essential hypertension, there 
was an increase in costs in cases where the guidelines were 
not followed, which indicates that more expensive drugs were 
prescribed instead of the first-line treatment consisting of 
cheaper drugs such as diuretics.
Study limitations
This study did not take into account the blood pressure of 
each patient; also, the small sample size (as it was a pilot 
study) did not give a precise picture of the management of 
hypertension patients. Further investigations are needed to 
support the results found for these populations.
Conclusion
The level of adherence to the guidelines is high in   Malaysian 
health-care prescribing patterns, but this percentage decreased 
with a coexisting disease, especially diabetes mellitus. Thus, the 
use of thiazide diuretics should be encouraged because they are 
well tolerated and inexpensive, and several large studies support 
the use of thiazide diuretics in the treatment of hypertension to 
reduce cardiovascular clinical events and stroke. In addition, 
the use of ACEI should be promoted as they have cardio- and 
renoprotective effects in diabetic patients. Perindopril should 
continue to be prescribed because it is relatively cheap and its 
daily dosage is beneficial. Hypertension treatment using diuret-
ics or BBs was more cost-efficient than with ARBs or CCBs. 
The results of this study also suggest the use of diuretics and 
CCBs in the elderly instead of BBs. Finally, the results of this 
study could help health care planners make better decisions con-
cerning the distribution of funds between medicinal options.
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